Intellia Therapeutics, Inc. NTLA

About Intellia Therapeutics, Inc. (NTLA): stock profile, AI score and financials

Intellia Therapeutics, Inc. (NTLA) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores NTLA at 18.0/100 on a composite quality score built from its SEC filings, placing it at rank #2,779 of 2,925 stocks — the bottom half of the AI-ranked universe. NTLA scores in the top quartile across institutional flow (99.0). Areas of concern include free cash flow (2.7) and profitability (3.1), which score below median versus the broader universe. Shareholder dilution risk is elevated at 2.7/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), Intellia Therapeutics, Inc. reports quarterly revenue of $7.7M, net income of $-106.6M, free cash flow of $-84.9M. Top institutional holders of NTLA by reported 13-F value include ARK Investment Management, BlackRock, STATE STREET, based on the most recent SEC filings. NTLA trades on the Nasdaq exchange and files with the SEC under CIK 1652130. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate NTLA daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Intellia Therapeutics, Inc. directly from SEC EDGAR.

Financials through the period ended Jun 30, 2026SEC EDGAR: CIK 1652130 →